The Urologic clinics of North America
-
Urol. Clin. North Am. · May 2005
ReviewThe current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
Urothelial transitional cell cancer has a high rate of response to combination cytotoxic therapy. Approximately 50% of patients with high-grade bladder cancer and deep muscle invasion ultimately die of disseminated disease. ⋯ This article reviews the use of adjuvant chemotherapy in localized or locally advanced transitional cell cancer. The chemotherapy of urological malignancies, including bladder cancer, has recently been reviewed in detail; this article does not contain an extensive review of the drugs used.